Skip to main content

387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies

Publication ,  Conference
Lin, C-C; Garralda, E; Schöffski, P; Hong, D; Siu, L; Martin, M; Maur, M; Hui, R; Soo, R; Chiu, J; Zhang, T; Ma, B; Kyi, C; Tan, D; Kwak, E ...
Published in: Regular and young investigator award abstracts
November 2020

Duke Scholars

Published In

Regular and young investigator award abstracts

DOI

Publication Date

November 2020

Publisher

BMJ Publishing Group Ltd

Conference Name

35th Anniversary Annual Meeting (SITC 2020)

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lin, C.-C., Garralda, E., Schöffski, P., Hong, D., Siu, L., Martin, M., … Braud, F. D. (2020). 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. In Regular and young investigator award abstracts. BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2020-sitc2020.0387
Lin, Chia-Chi, Elena Garralda, Patrick Schöffski, David Hong, Lillian Siu, Miguel Martin, Michela Maur, et al. “387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies.” In Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0387.
Lin C-C, Garralda E, Schöffski P, Hong D, Siu L, Martin M, et al. 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. In: Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020.
Lin, Chia-Chi, et al. “387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2020. Crossref, doi:10.1136/jitc-2020-sitc2020.0387.
Lin C-C, Garralda E, Schöffski P, Hong D, Siu L, Martin M, Maur M, Hui R, Soo R, Chiu J, Zhang T, Ma B, Kyi C, Tan D, Cassier P, Sarantopoulos J, Weickhardt A, Carvajal R, Spratlin J, Esaki T, Rolland F, Akerley W, Deschler-Baier B, Sabatos-Peyton C, Chowdhury NR, Gusenleitner D, Kwak E, Askoxylakis V, Braud FD. 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020.

Published In

Regular and young investigator award abstracts

DOI

Publication Date

November 2020

Publisher

BMJ Publishing Group Ltd

Conference Name

35th Anniversary Annual Meeting (SITC 2020)

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology